The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis

Gülsoy, Zuhal; GÜRSOY, Sinan; ÖZDEMİR KOL, İCLAL; KAYGUSUZ, KENAN; AVCI, Serdar Onur; YILDIRIM, Mehtap

doi:10.14744/etd.2019.22599

The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis

Mehtap YILDIRIM, (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

İclal Özdemir KOL, (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

Serdar Onur AVCI, (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

Zuhal GÜLSOY, (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

Kenan KAYGUSUZ, (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

Sinan GÜRSOY (Cumhuriyet Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Sivas, Türkiye)

Erciyes Medical Journal

8 0

Yıl: 2020 Cilt: 42 Sayı: 1 Sayfa Aralığı: 54 - 59 Metin Dili: İngilizce DOI: 10.14744/etd.2019.22599 İndeks Tarihi: 26-11-2020

The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis

Öz:

Objective: Continuous renal replacement therapy is made with high biocompatibility membranes that have high currentpower by using diffusion and convection together or separately. The aim of the present study was to compare the EMIC-2and AV600S filters used for continuous venovenous hemodiafiltration (CVVHDF) with respect to the effects on sepsis, theelimination of toxins that are elevated due to acute renal injury, and the effects on inflammatory mediators in severe sepsis.Materials and Methods: The study included 38 patients who were diagnosed with severe sepsis and were treated withhemodiafiltration in the intensive care unit. Acute Physiology and Chronic Health Evaluation—2 (APACHE-2) and SequentialOrgan Failure Assessment (SOFA) scores of the patients were calculated before CVVHDF starts. Hematocrit (Hct), whiteblood cell, blood pressure, heart rate, and body temperature values were measured and recorded. Procalcitonin (PCT), tumornecrosis factor alpha (TNF-α), interleukin (IL)-6, and IL-1 values on blood were also recorded before the process and at 8,16, and 24 h of the process.Results: When the AV600S filtered and EMIC-2 filtered groups are compared, TNF-α values are low in the EMIC-2 filteredgroup (p<0.05). There is no significant difference between the groups with respect to the measurements about APACHE-2,SOFA, IL-1β, IL-6, PCT, Hct, body temperature, mean blood pressures, and heart rate.Conclusion: We think that the filters do not cause a significant change on the elimination of inflammatory cytokines, exceptTNF-α, on limited numbers of patients who have sepsis with acute renal injury undergoing CVVHDF with EMIC-2 and AV600S.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Harris RL, Musher DM, Bloom K, Gathe J, Rice L, Sugarman B, et al. Manifestations of sepsis. Arch Intern Med 1987; 147(11): 1895–906.
2. Kaifei W, Sheling X, Kun X, Peng Y, Wanxue H, Lixin X. Biomarkers of Sepsis-Induced Acute Kidney Injury. BioMed Research International Volume 2018; 6937947: 7.
3. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331: 1338–42.
4. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9(6): R700–9.
5. Bellomo R, Parkin G, Love J, Boyce N. A prospective comparative study of continuous arteriovenous hemodiafiltration and continuous venovenous hemodiafiltration in critically ill patients. Am J Kidney Dis 1993; 21(4): 400–4.
6. Yaqub MS, Molitoris BA. Acute Kidney Injury. In: Lerma E, Berns JS, Nissenson A, editors. Current Diagnosis & Treatment Nephrology & Hypertansion. 1 st edition. USA: Mcgraw Hill Companies; 2009.pp. 89–98.
7. Shum HP, Chan KC, Yan WW, Chan TM. Treatment of Acute Kidney Injury Complicating Septic Shock with EMiC2 High-cutoff Hemofilter: Case Series. Indian J Crit Care Med 2017; 21(11): 751–7.
8. Atan R, Crosbie DCA, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of human studies. Renal Failure 2013; 35(8): 1061–70.
9. Kurt-Jones EA, Cao L, Sandor F, Rogers AB, Whary MT, Nambiar PR, et al. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect Immun 2007; 75(1): 471–80.
10. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115(6): 457–69.
11. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420(6917): 885–91.
12. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008; 36(4 Suppl): S198–203.
13. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294(7): 813–8.
14. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35(8): 1837–43.
15. Doherty C. Epidemyology of acute renal failure. In: Davison AM, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls CG, van Ypersele C, editors. Oxford Textbook of Clinical Nephrology. New York: Oxford University Press; 2005. Pp. 1435–43.
16. Lameire N, Biesen VW, Vanholder R. Epidemyology, Clinical evaluation, and prevention of acute renal failure. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive Clinical Nephrology. Philadelphia: Mosby; 2007. pp. 979–1000.
17. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med 2008; 36(2): 610–7.
18. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32(3): 801–5.
19. Wood JH, Partrick DA, Johnston RB jr. The inflamatory response to injury in children. Current Opinion in Pediatrics USA 2010; 22(3): 315–20.
20. Gedmintas A, Crilly J, Richards B, Comadira GP, Creamer J, Lind J, et al. Haemodynamic stability is maintained during extended Daily diafiltration in critically ill septic patients. Crit Care Resusc 2010; 12(3): 203–8.
21. Tamme K, Maddison L, Kruusat R, Ehrlich HE, Viirelaid M, Kern H, et al. Effects of high volume haemodiafiltration on inflammatory response profile and microcirculation in patients with septic shock. BioMed Research International 2015; 125615: 1–7.
22. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C; ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002; 62(5): 1855–63.
23. Hlad ík M, Tymonová J, Zaoral T, Kadlc ík M, Ad ámková M. Treatment by continuous renal replacement therapy in patients with burn injuries. Acta Chir Plast 2001; 43(1): 21–5.
24. Kade G, Literacki S, Rzeszotarska A, Niemczyk S, Lubas A. Removal of Procalcitonin and Selected Cytokines during Continuous Veno-Venous Hemodialysis Using High Cutoff Hemofilters in Patients with Sepsis and Acute Kidney Injury. Blood Purif 2018; 46(2): 153–9.
25. Eichhorn T, Hartmann J, Harm S, Linsberger I, König F, Valicek G, et al. Clearance of Selected Plasma Cytokines with Continuous Veno-Venous Hemodialysis Using Ultraflux EMiC2 versus Ultraflux AV1000S. Blood Purif 2017; 44(4): 260–6.
26. Atan R, Peck L, Visvanathan K, Skinner N, Eastwood G, Bellomo R, et al. High cut-off hemofiltration versus standard hemofiltration: effect on plasma cytokines. Int J Artif Organs 2016; 39(9): 479–86.
27. Balgobin S, Morena M, Brunot V, Besnard N, Daubin D, Platon L, et al. Continuous Veno-Venous High Cut-Off Hemodialysis Compared to Continuous Veno-Venous Hemodiafiltration in Intensive Care Unit Acute Kidney Injury Patients. Blood Purif 2018; 46(3): 248–56.
28. Peng Z, Pai P, Hong-Bao L, Rong L, Han-Min W, Chen H. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients. Cytokine 2010; 50(2): 186–91.
29. Gjyzari A, Muzi L, Morabito S. Continuous Renal Replacement Therapy for Acute Renal Failure in Critically III Patients and Early Predictive Factors. Bantao Journal 2007; 5(2): 58–60.

APA	YILDIRIM M, ÖZDEMİR KOL İ, AVCI S, Gülsoy Z, KAYGUSUZ K, GÜRSOY S (2020). The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. , 54 - 59. 10.14744/etd.2019.22599
Chicago	YILDIRIM Mehtap,ÖZDEMİR KOL İCLAL,AVCI Serdar Onur,Gülsoy Zuhal,KAYGUSUZ KENAN,GÜRSOY Sinan The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. (2020): 54 - 59. 10.14744/etd.2019.22599
MLA	YILDIRIM Mehtap,ÖZDEMİR KOL İCLAL,AVCI Serdar Onur,Gülsoy Zuhal,KAYGUSUZ KENAN,GÜRSOY Sinan The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. , 2020, ss.54 - 59. 10.14744/etd.2019.22599
AMA	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. . 2020; 54 - 59. 10.14744/etd.2019.22599
Vancouver	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. . 2020; 54 - 59. 10.14744/etd.2019.22599
IEEE	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S "The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis." , ss.54 - 59, 2020. 10.14744/etd.2019.22599
ISNAD	YILDIRIM, Mehtap vd. "The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis". (2020), 54-59. https://doi.org/10.14744/etd.2019.22599

APA	YILDIRIM M, ÖZDEMİR KOL İ, AVCI S, Gülsoy Z, KAYGUSUZ K, GÜRSOY S (2020). The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. Erciyes Medical Journal, 42(1), 54 - 59. 10.14744/etd.2019.22599
Chicago	YILDIRIM Mehtap,ÖZDEMİR KOL İCLAL,AVCI Serdar Onur,Gülsoy Zuhal,KAYGUSUZ KENAN,GÜRSOY Sinan The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. Erciyes Medical Journal 42, no.1 (2020): 54 - 59. 10.14744/etd.2019.22599
MLA	YILDIRIM Mehtap,ÖZDEMİR KOL İCLAL,AVCI Serdar Onur,Gülsoy Zuhal,KAYGUSUZ KENAN,GÜRSOY Sinan The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. Erciyes Medical Journal, vol.42, no.1, 2020, ss.54 - 59. 10.14744/etd.2019.22599
AMA	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. Erciyes Medical Journal. 2020; 42(1): 54 - 59. 10.14744/etd.2019.22599
Vancouver	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis. Erciyes Medical Journal. 2020; 42(1): 54 - 59. 10.14744/etd.2019.22599
IEEE	YILDIRIM M,ÖZDEMİR KOL İ,AVCI S,Gülsoy Z,KAYGUSUZ K,GÜRSOY S "The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis." Erciyes Medical Journal, 42, ss.54 - 59, 2020. 10.14744/etd.2019.22599
ISNAD	YILDIRIM, Mehtap vd. "The Effiacy of Continuous Venovenous Hemodiafitration with Cytokine Filter on Sepsis". Erciyes Medical Journal 42/1 (2020), 54-59. https://doi.org/10.14744/etd.2019.22599